Baduanjin Lower Elevated Blood PreSsure Study

NCT ID: NCT05397535

Last Updated: 2025-09-10

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 216 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-06-05
• Study Completion Date: 2025-07-11

Brief Summary

The aim of this study is to evaluate the effects of Baduanjin on blood pressure in individuals with high normal blood pressure (SBP 130-139 mmHg, and/or DBP 85-89 mmHg), as well as on glucose and lipid metabolism, quality of life, psychology, exercise, immune inflammation, endothelial function, and arterial stiffness.

Conditions

Elevated Blood Pressure

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: DOUBLE

Study Groups

Self-directed exercise group

Participants in the self-directed exercise group will choose the type and duration of exercise by their preference.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Brisk walking group

Participants in Brisk Walking Group will participate in brisk walking for 52 weeks (≥5 days/week, about 30 minutes/day).

Group Type: ACTIVE_COMPARATOR

Brisk walking

Intervention Type: BEHAVIORAL

Participants in this group will receive health education on hypertension and practice brisk walking on their own for at least 30 minutes, at least 5 days per week for 52 weeks. These participants will be required to do brisk walking regularly, and the researcher will monitor their adherence to practice and provide reminders if needed.

Baduanjin group

Participants in Baduanjin Group will practice Baduanjin singly for 52 weeks (≥5 days/week, about 30 minutes/day).

Group Type: EXPERIMENTAL

Baduanjin

Intervention Type: BEHAVIORAL

Participants in Baduanjin group will receive health education on hypertension and attend a 4-hour class to learn Baduanjin before receiving the interventions after the randomization. Baduanjin exercise protocol is based on the "Fitness Qigong Baduanjin Standard" enacted by the General Administration of Sports in 2003. Each Badaunjin exercise session will last at least 30 minutes and be conducted at least 5 days per week for 52 weeks. These participants will be required to practice Baduanjin regularly, and the researchers will monitor their adherence to practice and provide reminders if needed.

Interventions

Baduanjin

Participants in Baduanjin group will receive health education on hypertension and attend a 4-hour class to learn Baduanjin before receiving the interventions after the randomization. Baduanjin exercise protocol is based on the "Fitness Qigong Baduanjin Standard" enacted by the General Administration of Sports in 2003. Each Badaunjin exercise session will last at least 30 minutes and be conducted at least 5 days per week for 52 weeks. These participants will be required to practice Baduanjin regularly, and the researchers will monitor their adherence to practice and provide reminders if needed.

Intervention Type: BEHAVIORAL

Brisk walking

Participants in this group will receive health education on hypertension and practice brisk walking on their own for at least 30 minutes, at least 5 days per week for 52 weeks. These participants will be required to do brisk walking regularly, and the researcher will monitor their adherence to practice and provide reminders if needed.

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Age 40 years or older;
• Systolic blood pressure (SBP) <140 mmHg and diastolic blood pressure (DBP) <90 mmHg
• SBP 130-139 mmHg, and/or DBP 85-89 mmHg

Exclusion Criteria

• Diagnosis of hypertension (SBP≥140 mmHg, and/or DBP ≥90mmHg）
• History of cardiovascular diseases, such as coronary heart disease, heart failure, stroke, and peripheral vascular disease
• Diagnosis of chronic kidney disease, primary aldosteronism, Cushing's syndrome, or pheochromocytoma
• Newly diagnosed cancer or cancer metastasis within 5 years
• History of autoimmune disease
• Having taken antihypertensive drugs or immunoregulators within 2 weeks
• A long-term need for antihypertensive drugs or immunomoregulators
• Unable to maintain moderate intensity exercise due to illness or other reasons
• Pregnant, breastfeeding, or planning to become pregnant within the next 1 year
• Currently taking regular exercise (at least 30 minutes of moderate-intensity exercise at least three times a week)
• Allergic to sports bracelets
• Having participated or been participating in other clinical trials within the last 3 months
• Unable to use smartphones
• Other factors that may affect the follow-up, such as alcohol or substance abuse in the last 12 months, planing to live out of town for a long time, or diagnosis of dementia or cognitive impairment which indicates incapability of completing the study
• Unable to accurately measure blood pressure using the sphygmomanometer provided by the study due to a too large or too small arm circumference

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

China National Center for Cardiovascular Diseases

OTHER_GOV

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jing Li, MD,PhD

Role: PRINCIPAL_INVESTIGATOR

National Center for Cardiovascular Diseases

Locations

Fuwai Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

2022-1724

Identifier Type: -

Identifier Source: org_study_id